Purchaser/Employer

As purchasers of health care, we understand that you want your employees and their families to have access to the highest quality AND most cost effective care. As you may already be aware, hemophilia is a high cost, chronic condition that needs to be appropriately managed to ensure improved patient outcomes and to closely monitor the total cost of treatment. CCSC provides a framework through pilot programs, resources, and expert insights to identify key cost drivers and provide practical solutions to mitigate risks and increase cost savings. Join CCSC today to learn more about how you can improve access to high quality care and contain costs for your employees and their families.

Become a Member Already a member? Login

Benefits for Employers

Total cost of care analysis and education on cost containment strategies
Identification of key cost drivers and transparent strategic management tools to enable risk mitigation and drive significant savings
Facilitated value-based dialogue between payers and the provider experts throughout the hemophilia treatment center (HTC) network of federally recognized centers of excellence; integrated medical home treatment for hemophilia and other rare bleeding or clotting disorders.
Contracting pitfalls identified and recommendations made.

What is the Recommended Course of Action when an Employer Becomes Aware of Employees/Beneficiaries with Hemophilia?

Engage NHF’s payer team for early identification of strategies that will enable lowest total cost of care management
Determine if hemophilia care is being delivered by an HTC
Utilize risk mitigation strategies aimed at ensuring transparency and the cost effective delivery of the required specialty biologic drug treatments; which make up >85% of the total cost of care
Be aware of the unintended consequences of copay assistance and accumulator adjustments programs
Consider the potential of unintended consequences before applying an accumulator adjustment program as a one size fits all option to patients with hemophilia, who have no cheaper generic equivalents available and to best manage total cost of care, must be proactive, not reactive.¹

References: 1. Soucie JM, et al. Blood. 2000;96:437-442.